Imunofan after surgery for acute peritonitis in children
I. V. Nesterova, G. A. Chudilova, V. N. Chapurina, S. V. Kovaleva, Yu. V. Teterin, N. K. Barova, D. E. Lyagusha, V. A. Tarakanov · 2022 · Medical Immunology (Russia). 2022;24(3):553–572.
Reported findings and study design
In local peritonitis, 7 children received the adjunct and 3 received standard care. In diffuse disease, the groups had 5 and 3 children. Another 18 healthy children provided laboratory reference values. The investigators used blood flow cytometry to measure neutrophil subsets and tested phagocytosis and oxidative-burst activity before and after treatment.
Dose, route and schedule
Both groups received postoperative standard care. The Imunofan groups received 1 mL intramuscularly on five consecutive days, then on alternate days, for six injections in local disease and ten in diffuse disease. The figure’s concentration unit conflicts with the injectable product label.
Protocol source ↗ · Original journal article, Figure 2
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ICU stay in diffuse peritonitis | 2 (1.0–2.5) versus 4 (3.5–4.0) days | Imunofan plus standard care (n = 5) versus standard care (n = 3). Medians and reported intervals. · Reported p < 0.05 |
| CD64-positive neutrophil subset in diffuse disease | 60.7% to 0.74% | Within the Imunofan arm. Standard-care subgroup showed no significant change on this measure. · Within-arm p < 0.05 |
| Time to fever normalization in diffuse disease | 4 (3.0–4.5) versus 6 (5.5–6.5) days | Imunofan plus standard care (n = 5) versus standard care (n = 3). · Reported p < 0.05 |
| Drain removal in diffuse disease | 3 (2–3) versus 5 (4.5–5.0) days | Reported p < 0.05 |
| CD64-negative neutrophil subset in diffuse disease | 29.6% to 95.97% | Within the Imunofan arm. Standard-care endpoint was 40.1%. Healthy reference median was 93.3%. · Within-arm p < 0.05 |
| Actively phagocytosing neutrophils in diffuse disease | 62% to 71% | Within the Imunofan arm. · Reported p < 0.05 |
| Stimulated oxidative-burst assay in local disease | 7.5% to 17.0% formazan-positive cells | Within the Imunofan arm. The separate cytochemical index changed from 0.46 to 0.49 (p > 0.05). · Reported p < 0.05 for cell percentage |
| Local disease: phagocytosis and digestive activity | Several changes did not reach statistical significance | The authors report p > 0.05 for the actively phagocytosing cell fraction, digestive activity and particle uptake in the Imunofan arm. |
The ICU comparison rests on eight children, and the marker results include changes from baseline. The study does not establish a reliable clinical treatment effect.
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The clinical groups had only 3–7 children each. The study does not describe random assignment or blinded outcome assessment.
- The paper reports bowel paresis in 80% of the diffuse comparison group, but lists three patients in that group. The percentage has no reconcilable event count.
- The related 2022 Effective Pharmacotherapy article repeats the same arm sizes, clinical timings and several marker values. Its patient counts are not added as a separate cohort.
- Figure 2 prints a concentration unit that conflicts with the product insert. The administered peptide mass is unconfirmed.
Related publications may cover the same research program or participants.
Source access
Original article methods, clinical results, Figures 2–6 and selected neutrophil assays. The 2022 companion reports identical treatment-group sizes and repeats key outcomes.
Source reviewed 2026-11-10.
Source type: Original journal article, author-shared copy
Citation and original source
Original source: I. V. Nesterova, G. A. Chudilova, V. N. Chapurina, S. V. Kovaleva, Yu. V. Teterin, N. K. Barova, D. E. Lyagusha, V. A. Tarakanov. Imunofan after surgery for acute peritonitis in children Medical Immunology (Russia). 2022;24(3):553–572. 2022.
Molekul research summary: https://molekul.io/research/nesterova-imunofan-peritonitis-2022. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry